Stay updated with breaking news from Nasdaq Beam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $56.00 price target on the stock. Cantor Fitzgerald’s price target points to a potential upside of 136.39% from the company’s previous close. […]
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have received an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average […]
Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $24.80 and last traded at $24.92, with a volume of 156835 shares. The stock had previously closed at $25.55. Analyst Ratings Changes A number of research firms have recently […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends. Risk & Volatility Beam Therapeutics has a beta […]
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) issued its earnings results on Tuesday. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.34, Briefing.com reports. The company had revenue of $20.12 million during the quarter, compared to analysts’ expectations of $17.32 million. Beam Therapeutics had a negative net margin […]